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Intrabone marrow injection enhances placental mesenchymal stem cell
mediated support of hematopoiesis in mice
1, ,

1

2,

1

1

1

1

Ya Hong YUAN * **, Chun Fang ZHOU **, Zhi Yong LU , Xiao Li WANG , Yan DING , Dongsheng LI
Hubei Key Laboratory of Embryonic Stem Cell Research, Tai-He Hospital, Hubei University of Medicine, Shiyan, Hubei, P.R. China
2
Department of Gastroenterology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, P.R. China
Received: 30.11.2014

Accepted/Published Online: 03.04.2015

Final Version: 05.01.2016

Background/aim: In order to determine the synergistic effects of human placental mesenchymal stem cells (PMSCs) on hematopoiesis
in vivo, we compared the intrabone marrow injection (IBMI) with the conventional intravenous injection (IVI).
Materials and methods: C57BL/6 recipient mice conditioned with lethal doses of irradiation were transplanted with bone marrow
mononuclear cells (MNCs) and bone marrow-derived mesenchymal stem cells (BMSCs) from BALB/c mice by IBMI or IVI. NOD/
SCID recipient mice conditioned with sublethal doses of irradiation were transplanted with human umbilical cord blood MNCs (UCBMNCs) and PMSCs by IBMI or IVI.
Results: The number of hematopoietic cells was significantly higher in mice transplanted with BMSCs by IBMI than in those transplanted
by IVI in a murine transplantation model (BALB/c→C57BL/6). Moreover, the percentage of human hematopoietic cells in the tibiae of
the NOD/SCID mice that were transplanted with PMSCs plus UCB-MNCs was higher than that in mice transplanted with UCB-MNCs
alone. In addition, in mice that were transplanted with PMSCs, PMSCs injected by IBMI were more efficient than those injected by IVI.
Conclusion: Our results not only elucidated the role of PMSCs in promoting hematopoiesis, but also revealed the therapeutic potential
of the combination of PMSCs and IBMI in transplantation.
Key words: Placental mesenchymal stem cells, mononuclear cells, intrabone marrow injection, hematopoietic reconstruction

1. Introduction
Bone marrow transplantation (BMT) has been widely
used for the treatment of a variety of diseases, including
hematological diseases, autoimmune diseases, and
cancers (1–3). A healthy bone marrow hematopoietic
microenvironment (HME) is of great significance for
the implantation of hematopoietic stem cells (HSCs)
and hematopoietic recovery. In clinical BMT, the bone
marrow HME is often damaged by chemotherapy prior to
transplantation, resulting in a slow recovery of the recipient’s
HME. Mesenchymal stem cells (MSCs) are an important
element of the bone marrow HME and can differentiate
into various stromal cells of mesenchymal origin. In this
microenvironment, MSCs supply an appropriate scaffold
for hematopoiesis and a complex network of cytokines,
adhesion molecules, and extracellular matrix proteins that
regulate survival, proliferation, growth, and differentiation
of HSCs (4–6). Studies have demonstrated that
mesenchymal stem cells (MSCs) support hematopoiesis

and enhance the engraftment of hematopoietic cells after
cotransplantation (7,8). The cotransplantation of human
MSCs and HSCs results in increased chimerism and
accelerates hematopoietic recovery in both patient and
animal models (9–12).
The classic BMT approach is to inject bone marrow
(BM) or HSCs into the recipient’s blood, where HSCs find
“niches” in the BM to “seed,” a process commonly referred
to as “homing.” In the case of conventional intravenous
BMT (IV-BMT), the majority of bone marrow cells
(BMCs), both HSCs and MSCs, are trapped in the lung and
liver, where host cells kill the BMCs (13–15). To overcome
this problem, transplantation using an intrabone marrow
injection (IBMI) of hematopoietic stem/progenitor cells
(HS/PCs) has been developed. Studies have demonstrated
that intrabone marrow transplantation (IBMT) is an
advantageous strategy for allogeneic BMT over the
conventional IV-BMT (16). Nonetheless, in terms of
MSCs, it is not clear whether transplantation through IBMI
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would enhance hematopoiesis better than transplantation
through IVI. In the present study, we established two
transplantation models to compare the efficacy of
hematopoiesis reconstruction after transplanting MSCs by
IBMI or by IVI.
Unlike all of the above-mentioned studies, which
used bone marrow-derived MSCs (BMSCs), we also used
placenta-derived MSCs (PMSCs) in our transplantation
models. It has been shown that the placenta yields a
large amount of MSCs from the fetal membrane with
high plasticity that is capable of differentiating into both
natural mesodermal and nonmesodermal lineages (17,18).
These characteristics are similar to those of BMSCs (19).
However, the PMSCs do not have the drawbacks associated
with using BMSCs in clinical application. For example,
large quantities of infused cells are required for treatment
but the amount of donor BM is limited. Furthermore, the
collection of donor BM is an invasive procedure. There is
also the possibility that BMSCs might be contaminated
with malignant cells if harvested from patients with a
hematological malignancy (e.g., leukemia). Therefore, the
PMSCs may be the ideal succedaneum of BMSCs. It is
not known, however, whether PMSCs are able to support
hematopoiesis in vivo.
In the present study we determined the effects of human
PMSCs on hematopoiesis in vivo. We also compared IBMI
to IVI to assess their synergistic effect with PMSCs on
hematopoiesis.
2. Materials and methods
2.1. Cell isolation and culture
BABL/c mouse BMSC cell line BABL-5043 was purchased
from American Cell Biologics Company, USA. Cell lines
were grown in α-MEM medium supplemented with 10%
fetal bovine serum. The PMSCs were generated from
full-term placentae of healthy volunteers and collected
according to procedures approved by the local ethics
committee. The cells were isolated as previously reported
(19). Briefly, the placental tissue was dissected, digested
in enzymatic mixtures, and homogenized. A single-cell
suspension was cultured in a complete medium comprising
Dulbecco’s modified Eagle’s medium-low glucose (Gibco,
USA) supplemented with 10% heat-inactivated fetal bovine
serum (FBS) (Gibco) at 37 °C in 5% CO2. The medium was
replaced one to two times each week. After three passages,
the cells were ready for use in the experiment. PMSCs
were identified by morphology under a light microscope
and assayed routinely for the presence of MSC-related cell
surface antigens by flow cytometry analysis. Additionally,
the PMSCs were cultured in adipogenic and osteogenic
medium to estimate their potential for differentiation.
BMCs were flushed from the medullary cavities of the
humeri, femora, and tibiae of BALB/c mice, using a 26-G

needle attached to a 1-mL syringe, into phosphate-buffered
saline with 2% fetal calf serum and filtered through a 70µm nylon mesh. Bone marrow mononuclear cells (BMMNCs) were isolated from the BMCs on a Ficoll–Hypaque
density gradient (1.077 g/mL, Pharmacia, USA) after
centrifugation for 25 min at 400 × g.
Human umbilical cord blood (hUCB) samples were
obtained from full-term deliveries after informed consent
of the mother and were used in accordance with the
local ethics committee. The hUCB was collected in bags
containing heparin (Shandong Weigao Group Co., Ltd.,
China) and processed within 24 h. Samples were diluted
1:2 in PBS. Human umbilical cord blood mononuclear
cells (UCB-MNCs) were collected after centrifugation on
Ficoll–Hypaque density gradient (1.077 g/mL, Pharmacia)
and washed in PBS.
2.2. Mice
Seven-week-old female C57BL/6 (H-2b), BALB/c (H-2d),
and NOD/SCID mice were purchased from the Animal
Experiment Center of Wuhan University (China) and
maintained under pathogen-free conditions in our animal
facility throughout the study. C57BL/6 and NOD/SCID
mice were irradiated lethally (8 Gy) and sublethally (2.5
Gy), respectively, 16–18 h before transplantation. Gammairradiation was delivered with a Gammacell 40 Exactor
with 60Co sources at a dose of 1.0 Gy/min.
2.3. Flow cytometry assay
Cells were harvested from the cell culture, BM, spleen, or
blood and washed with PBS. Cells were then stained with
fluorochrome-conjugated antibodies against some cell
surface markers. The staining of an IgG isotype was used
as a control. After washing, the cells were analyzed by flow
cytometry for the expression of each surface marker.
2.4. Intrabone marrow and intravenous injection
For IBMI, mice were anesthetized with an intraperitoneal
injection of 0.05 g/g body weight of a 1% solution of
pentobarbital sodium and the knee joint was flexed. A
hole was drilled into the tibia with a short, 27-gauge
needle attached to a 3-mL syringe filled with PBS. The first
needle was then removed and replaced with a 28-gauge
needle attached to a 0.3-mL insulin syringe containing
the indicated number of cells in 30 µL of substrate for
delivery. For IVI, cells were injected into the tail vein of
the recipient mice.
2.5. Experimental protocols of transplantation
Two transplantation models were established in the study.
First, with the lethal dose of irradiation, the C57BL/6
recipient mice were transplanted with BM-MNCs and
BMSCs from the BALB/c mice by IBMI or IVI (Figure
1). Sixty recipient mice were randomly divided into three
groups. In the IBM1 group, 1 × 106 BMSCs were injected
into the left tibial marrow cavity and 2 × 107 BM-MNCs
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Figure 1. Experiment protocol of the BALB/c→C57BL/6 model. The number and infusion way
of BMSCs and BM-MNCs are shown.

were injected into the C57BL/6 mice by IVI. In the IBM2
group, 1 × 106 BMSCs were injected into the left tibial
marrow cavity and 1 × 107 BM-MNCs were injected into
the C57BL/6 mice by IVI. In the IV group, 1 × 106 BMSCs
and 2 × 107 BM-MNCs were injected into the C57BL/6
mice by IVI.
Second, with the sublethal dose of irradiation, recipient
NOD/SCID mice were transplanted with human UCBMNCs and PMSCs by IBMI or IVI (Figure 2). Thirty-six

recipient mice were randomly divided into the following
three groups: group a (PMSCs by IBMI; UCB-MNCs by
IVI), group b (PMSCs + UCB-MNCs by IVI), and group
c (UCB-MNCs by IVI). In group a, 1 × 106 PMSCs were
injected into the left tibia by IBMI, and 3 × 107 UCBMNCs were injected into the same recipient mice by IVI.
In group b, 1 × 106 PMSCs and 3 × 107 UCB-MNCs were
injected into recipient mice by IVI. In group c, only 3 ×
107 UCB-MNCs were injected into recipient mice by IVI.

Figure 2. Experiment protocol of the human PMSCs→NOD/SCID model. The number and
infusion way of PMSCs and UCB-MNCs are shown.
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2.6. Detection of hematopoietic reconstruction in
recipient mice
For BALB/c→C57BL/6 transplantation, C57BL/6
recipient mice were sacrificed on days 1, 3, 6, or 9 after
transplantation, and the BM was flushed from the injected
and contralateral tibiae. Lysis of the red cells was performed
using a red blood cell lysis buffer (Sigma, USA). The
nucleated cells were stained with a PE-conjugated anti-H2Kd mAb (BD Pharmingen, USA) to identify the BALB/cderived cells. To detect the hematopoietic reconstruction
in the recipient mice, the nucleated cells were stained with
an FITC-conjugated anti-CD45 mAb and biotinylated
anti-Gr-1, anti-CD11b, and anti-B220 mAb, followed by
streptavidin-cychrome (BD Pharmingen). The stained
cells were analyzed using FACScan (BD Biosciences, USA)
equipped with CellQuest software.
For human PMSCs→NOD/SCID transplantation,
recipient mice were sacrificed on day 14 after
transplantation. BMCs were flushed from the injected and
contralateral tibiae. The nucleated cells were counted and
stained with FITC-conjugated antihuman CD45 and PEconjugated antihuman CD34 mAbs. At week 6, recipient
mice were sacrificed, cells were recovered from the tibiae,
spleens, and peripheral blood. To obtain splenocytes,
spleens were ruptured, homogenized, filtered through
a 40-µm nylon mesh, centrifuged, and subjected to red
blood cell lysis. The nucleated cells were stained with
FITC-conjugated human anti-CD45, anti-CD34, antiCD14, anti-CD19, and anti-CD56 mAbs (eBioscience,
USA). The percentage of human-derived hematopoietic
cells was analyzed by flow cytometry.
2.7. Statistical analysis
The results represent samples from more than three mice
per experiment. Statistical analysis was performed with
the use of SPSS 19.0. Statistical comparisons between
the two groups were performed by using Student’s t test.
Probability (P) values of < 0.05 were considered significant.
3. Results
3.1. Identification of PMSCs
PMSCs were characterized by plastic adhesion and
fibroblastic morphology by light microscopy. These cells
are able to differentiate into osteocytes, chondrocytes,
and adipocytes under specific differentiation conditions.
During the culture of primary cells, we saw that a few
attached MSCs stretched from a small tissue mass and
had obtained the shape of a typical fibroblast in 4–6 days
(Figure 3A, I). After 10 to 14 days, the cells formed a
monolayer of homogeneous, bipolar, spindle-like cells in a
whirlpool-like array (Figure 3A, II). These cells grew, were
firmly attached to the bottom of the flask, and required
tryptic digestion for cell passage.

To phenotypically characterize these freshly isolated
placental MSCs, we stained the cells with a panel of surface
markers and analyzed them by flow cytometry. As shown
in Figure 3B, these cells did not express CD45, suggesting
that they were not hematopoietic cells. The cells also
lacked CD34 expression, indicating that they differed from
hematopoietic stem cells. However, these cells expressed
mesenchymal cell markers such as CD29, CD44, CD105,
CD106, and CD166. To further confirm whether these
placental cells were MSCs, we assessed their potential to
differentiate into several tissue lineages. To do this, we
cultured these placental cells in an OsteoDiff or AdipoDiff
induction medium (Miltenyi Biotec GmBH) for 3 weeks
and measured osteogenesis and adipogenesis by alkaline
phosphatase (ALP) and oil red O staining, respectively. As
shown in Figure 3C, the cells stained positively for ALP
after a 3-week culture, suggesting extracellular calcium
deposition, a key marker of osteogenesis. When cultured in
the AdipoDiff induction medium for 3 weeks, cells stained
positively for fat droplets, a feature of adipogenesis. Taken
together, these results indicated that these placental cells
displayed a similar morphology, phenotype, and function
as MSCs did. Therefore, the cells were identified as PMSCs.
3.2. Effects of transplantation BMSCs by IBMI on
hematopoiesis in mice
We next employed a mouse transplantation model to test
whether transplantation BMSCs by IBMI enhance the
growth of hematopoietic cells in vivo. BM-MNCs from
the BALB/c mice were transplanted into C57BL/6 mice by
IVI. BMSCs from the BALB/c mice were transplanted into
C57BL/6 mice by IBMI or by IVI. The recipient C57BL/6
mice were sacrificed at various times (days 1, 3, 6, and 9)
after IBMI or IVI. BMCs were prepared from the injected
and contralateral tibiae, double-stained with anti-H-2Kd
mAb (donor-type) and some hematopoietic cell markers,
and analyzed by FACScan. As shown in Figure 4A, the total
number of BMCs increased in a time-dependent manner
after transplantation in all groups, with a higher number of
BMCs in the IBM1 or IBM2 group than in the IV group (P
< 0.05) on day 6. This difference was reflected in the donorderived cells (H-2Kd+) as we observed that the number of
H-2Kd+ cells in the IBM1 or IBM2 group was significantly
higher than that in the IV group (P < 0.05) on day 6 or 9
(Figure 4B). Similarly, after transplantation, the number of
H-2Kd+ cells increased in a time-dependent manner in all
groups with the lowest increased rate in the IV group.
To trace the myeloid and lymphoid lineage cells,
we measured the number of H-2Kd+/Gr-1+ (Figure 4C),
H-2Kd+/CD11b+ (Figure 4D), and H-2Kd+/B220+ cells
in donor-derived BMCs from recipient mice. Similar to
H-2Kd+ cells, Gr-1+ or CD11b+ cells proliferated over time
after transplantation. Again, we found that the number of
Gr-1+ or CD11b+ cells was significantly higher in the IBM1
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Figure 3. Isolation and characterization of placenta-derived cells. (A) Morphology of placenta-derived cells under light microscopy.
Freshly isolated placental cells were cultured for 4–6 days (I) or 10–14 days (II). Fibroblast-like colonies were seen. Bar = 50 µm.
(B) Immunophenotype of placenta-derived cells. Cells were stained with fluorochrome-conjugated antibodies against CD29, CD34,
CD44, CD45, CD105, CD106, CD166, HLA-DR, or immunoglobulin isotype control antibodies and analyzed by flow cytometry. (C)
Differentiation potential of placenta-derived cells. Cells were cultured in an osteogenic (I) or adipogenic (II) medium for 3 weeks and
stained with ALP for calcium deposition or oil red O. Magnification: I, ×100; II, ×400. Bar = 10 µm.
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Figure 4. Effects of transplantation of BMSCs through IBMI and IVI on hematopoiesis in mice. BMSCs and BM-MNCs from the BALB/c
mice were transplanted into C57BL/6 mice through IBMI or IV. The recipient C57BL/6 mice were then sacrificed at the indicated time
points. A graph showing the total BMC (A), donor-derived (B), donor-derived Gr-1+ (C), and donor-derived CD11b+ cell numbers (D).

or IBM2 group than in the IV group (P < 0.01) on day
6 or 9. Among the BMCs, the number of H-2Kd+/B220+
cells was always very low and no difference was observed
between the IBM and IV groups. Summarized results from
multiple samples clearly showed that MSC transplanted by
IBMI enhanced hematopoietic cell growth more strongly
than those transplanted by IVI. The numbers of total
BMCs, donor-derived BMCs, Gr-1+ cells, and CD11b+
cells were higher in the IBM group than they were in
the IV group on day 6 after transplantation (P < 0.05)
(Figure 5A). We observed in a representative transplanted
mouse that the percentage of donor-derived nucleated
cells (H-2Kd+/CD45+) and myeloid cells (H-2Kd+/Gr-1+
and H-2Kd+/CD11b+ cells) was higher in the IBM groups
than in the IV group. This increase was more obvious in
the IBM1- or IBM2-injected tibia of mice (Figure 5B).
Taken together, these results clearly indicated that MSCs

transplanted by IBMI were superior to those transplanted
by IVI in facilitating hematopoietic cell growth.
3.3. Effects of human PMSCs transplantation on
hematopoietic reconstruction in NOD/SCID mice
Next, we wanted to examine hematopoietic reconstruction
in
sublethal-dose-irradiated
NOD/SCID
mice
transplanted with human PMSCs and UCB-MNCs by
IBMI or IVI. BMCs in tibiae (injected or contralateral)
were harvested 14 days after transplantation and analyzed
by flow cytometry (Figure 6A). The transplantation of
PMSCs promoted hematopoietic reconstitution in NOD/
SCID mice, as the percentage of human CD45+ cell in the
injected or contralateral tibiae of the mice cotransplanted
with PMSCs and UCB-MNCs (groups a and b, 63.5%
and 20.6%, respectively) was higher than that of mice
transplanted with UCB-MNCs alone (group c, 8.6%).
Moreover, the percentage of human CD34+ cells in the
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Figure 5. A summary of donor cell engraftment levels in the BM of recipient mice 6 days after transplantation. (A) A graph showing the
total BMC (a), total donor-derived (b), donor-derived Gr-1+ (c), and donor-derived CD11b+ (d) cell numbers. (**P < 0.01; *P < 0.05). (B)
Representative dot plots showing the expression of CD45, CD11b, Gr-1, or B220 in recipient C57BL/6 mice transplanted with BMSCs
and BM-MNCs from the BALB/c mice by IBMI or IVI.

injected or contralateral tibiae of the mice in group a and
group b (9.6% and 2.5%, respectively) was higher than that
in the mice of group c (0.9%). Actually, human cells were
hardly detected, and the number of CD45+ and CD34+
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cells was extremely low in group c (Figure 6B). Supporting
this finding, when transplanted with PBMCs by IBMI and
UCB-MNCs through a vein (group a), NOD/SCID mice
had a significant increase in the percentage of CD45+ and

YUAN et al. / Turk J Med Sci

Figure 6. Effects of human PMSCs transplantation on hematopoietic reconstruction in NOD/SCID mice. (A) Representative dot plots
showing growth of human CD45+ or CD34+ cells in the tibia of NOD/SCID mice on day 14 after transplantation by flow cytometry.
(B) A graph showing the percentage of human CD45+ and CD34+ cells in the tibia of NOD/SCID mice on day 14 after transplantation.
Group c was compared with group a or group b; *P < 0.05. Group a was compared with group b, *P < 0.05; **P < 0.01. (C) Representative
histograms showing growth of human hematopoietic cell in the tibia of NOD/SCID mice at week 6 after transplantation.

CD34+ cells as compared with mice in group c (Figure
6B). In addition, in group a the percentage of human
CD45+ and CD34+ cells was higher than that in group b,

demonstrating that PMSCs transplanted by IBMI were
more efficient than cells transplanted by IVI.
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To investigate the later hematopoietic reconstitution of
NOD/SCID mice, we measured the percentage of human
CD45+, CD34+, CD14+, CD19+, and CD56+ cells in the
BM, spleen, and blood 6 weeks after transplantation by
flow cytometry. As shown in the Table, we again found
that transplantation with PMSCs plus UCB-MNCs
significantly enhanced the growth of these human cells as
compared with transplantation with UCB-MNCs alone
(P < 0.05). Moreover, the percentages of all these human
cells in bone marrow were higher when PMSCs were
transplanted by IBMI than when cells were transplanted
by IVI. As shown in Figure 6C, we displayed the FACS
pictures of representative transplanted mice in the three
groups. However, it was difficult to detect the presence
of these hematopoietic cells in the spleen or blood. These
results suggest that the reconstruction of hematopoiesis
was more promising in the BM than in the peripheral
lymphoid organs.
4. Discussion
In the present study, we evaluated the effects of IBMI on
human PMSCs-mediated hematopoietic reconstruction
in NOD/SCID mice and found that mouse BMSCs
transplanted by IBMI were superior to those transplanted
by IVI. In addition, we found that the PMSCs isolated
in the present study demonstrated features similar to

BMSCs for improving hematopoietic cells implanted
in vivo (20). In the (BALB/c→C57BL/6) mouse model,
the reconstruction of BMCs, donor-derived cells, and
donor-derived myeloid lineage cells in the tibial cavity
was quicker in the IBM group than it was in the IV group.
The percentage of donor-derived nucleated cells reached
over 90% on posttransplantation day 6, consistent with a
previous report (21). Even though they were transplanted
with half of the cells, IBM-transplanted mice experienced
a faster hematopoietic cell reconstruction than IVtransplanted mice, confirming that MSCs transplanted
by IBMI were more efficient than those transplanted by
IVI. Similar results were seen in myeloid (Gr-1+; CD11b+)
hematopoietic reconstruction. An explanation for this
observation is that if BMSCs are directly injected into the
BM cavity, MSCs could remain at the BM site and could
proliferate and differentiate. MSCs are the precursor cells
of mesenchymal cell types in the hematopoietic niche,
and adipocytes, osteoblasts, and fibroblasts represent an
important, defining cell type of this niche (22). Through
IBMI, MSCs repaired the injuries of the hematopoietic
niche caused by irradiation and provided a supportive
role for the hematopoietic microenvironment that enabled
the engraftment of HSCs. Moreover, when an osteoblastic
niche was generated through cotransplantation with MSCs,
the engraftment of HSCs was enhanced (23). However,

Table. Analyses of surface antigens on donor-derived cells in NOD/SCID mice 6 weeks posttransplantation.
Cell surface antigen (%)

Mice

CD45

CD34

CD14

CD19

CD56

Group a
BM(injected)

24.6(±5.6) **△

2.1(±1.4)*△

10.4 (±4.0) **△

5.9(±3.1)*△

4.7(±2.1)*

BM (contralateral)

15.9 (±4.3)*

1.8(±1.1)

7.4 (±3.7) *

3.5(±2.3)*

2.6(±1.8)*

△

Spleen

1.7 (±1.2)

2.7(±1.8)

3.6 (±1.9)

ND

1.7(±1.1)

Blood

1.9(±0.9)

ND

ND

ND

ND

1.6(±0.9)

5.0 (±3.9)*

3.3 (±1.8)

4.1 (±2.3)*

Group b
BM

11.0(±3.8)*

Spleen

1.9(±0.7)

1.2 (±1.1)

2.7(±1.3)

1.9 (±0.7)

2.0 (±1.1)

Blood

0.6(±0.4)

0.6(±0.5)

ND

ND

ND

BM

3.9(±2.8)

1.3(±0.7)

2.3 (±1.9)

2.8 (±1.8)

1.2 (±0.6)

Spleen

2.4 (±1.1)

ND

1.8 (±0.6)

ND

ND

Blood

1.4 (±0.8)

ND

ND

ND

ND

Group c

Results are expressed as means ± SD for 3–6 mice. Asterisks represent the P values of BM of group a and group b versus BM of group
c;*P < 0.05; **P < 0.01; Triangles represent the P values of group a injected and contralateral versus BM of group b; △P < 0.05.
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MSCs cannot home to or engraft in the BM if transplanted
through the veins (24). In addition, MSCs in the bone
marrow facilitated HSC homing to the BM and might play
an important role in promoting hematopoiesis. It has been
shown that CXCR4 is expressed on the surface of MSCs
and BM stromal cells (25,26) and the SDF-1/CXCR4 axis
plays an essential role in directing engraftment of HSCs
into the BM after transplantation (27,28). Thus, through
IBMI, MSCs did not only dwell in bone marrow to support
the hematopoietic microenvironment, but also promoted
the HSCs to home to BM and accelerate the hematopoietic
recovery by generating some cytokines.
Although BM-MSCs may have promoting effects on
HSC engraftment and repopulation (29), BM collection
involves invasive procedures. In addition, the number of
BM-MSCs decreases with age. The easy access, the ability
to repeatedly use it, and the uncomplicated enzymebased isolation procedure make placental tissue the
most attractive source of MSCs. However, the capacity of
PMSCs to support hematopoiesis in vivo was not clear. In
the present study, we found that human PMSCs improve
hematopoietic recovery in vivo. Therefore, PMSCs may
be an ideal alternative source of BMSCs for basic research
and clinical applications. Further studies are required
to better understand the supportive effects of PMSCs
on hematopoiesis in vitro and in vivo as well as its great
therapeutic potential.

In addition, the IBMI is safe and effective for the clinical
application of PMSCs in the future. IBMI has been used
clinically as a technique to deliver medications (30), blood
products, and fluids to critically ill children and wounded
soldiers (31–33). In these studies, this technique was safely
performed in thousands of patients. Interest in IBMI
has now been renewed in the field of hematopoietic cell
transplantation. Both, in clinical settings and in murine
models, the IBMI delivery of hematopoietic grafts and
lymphocytes may reduce the risk of acute graft-versus-host
disease (GVHD) (34). Intra-BM cord blood transplants
in patients with malignant hematopoietic diseases are
associated with high rate of engraftment and early and
robust platelet recovery (35). The available clinical data are
encouraging and at this point IBMI can be recommended
for clinical application.
In conclusion, we generated MSCs from placental tissue
and found that PMSCs supported hematopoiesis in vivo.
Our data clearly showed that, for enhancing the PMSCmediated support of hematopoiesis, transplantation
through IBMI was superior to that through IVI.
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